The DOI matches its Crossref record.
Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study)
Open accessAbstract
Entecavir (ETV) is a potent inhibitor of hepatitis B viral replication, but long‐term therapy may be required. We investigated whether adding on pegylated interferon (Peg‐IFN) to ETV therapy enhances serological response rates. In this global investigator‐initiated, open‐label, multicenter, randomized trial, hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B (CHB) patients with compensated liver disease started on ETV monotherapy (0.5 mg/day) and were randomized in a 1:1 ratio to either Peg‐IFN add‐on therapy (180 µg/week) from week 24 to 48 (n = 85) or to continue ETV monotherapy (n = 90). Response was defined as HBeAg loss with HBV DNA <200 IU/mL at week 48. Responders discontinued ETV at week 72. All patients were followed until week 96. Response was achieved in 16 of 85 (19%) patients allocated to the add‐on arm versus 9 of 90 (10%) in the monotherapy arm (P = 0.095). Adjusted for HBV DNA levels before randomized therapy, Peg‐IFN add‐on was significantly associated with response (odds ratio: 4.8; 95% confidence interval: 1.6‐14.0; P = 0.004). Eleven (13%) of the add‐on‐treated patients achieved disease remission after ETV cessation versus 2 of 90 (2%) of those treated with monotherapy (P = 0.007), which was 79% (11 of 14) versus 25% (2 of 8) of those who discontinued ETV (P = 0.014). At week 96, 22 (26%) patients assigned add‐on versus 12 (13%) assigned monotherapy achieved HBeAg seroconversion (P = 0.036). Peg‐IFN add‐on led to significantly more decline in hepatitis B surface antigen, HBeAg, and HBV DNA (all P < 0.001). Combination therapy was well tolerated. Conclusion: Although the primary endpoint was not reached, 24 weeks of Peg‐IFN add‐on therapy led to a higher proportion of HBeAg response, compared to ETV monotherapy. Add‐on therapy resulted in more viral decline and appeared to prevent relapse after stopping ETV. Hence, Peg‐IFN add‐on therapy may facilitate the discontinuation of nucleos(t)ide analogs. (H epatology 2015;61:1512–1522)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update
Sarin, S. K., Kumar, M., Lau, G. K., Abbas, Z., Chan, H. L. Y., Chen, C. J., Chen, D. S., Chen, H. L., Chen, P. J., Chien, R. N., et al. (2016) · Hepatology International · doi:10.1007/s12072-015-9675-4 · Cited by 2,550
Approved Antiviral Drugs over the Past 50 Years
De Clercq, E., & Li, G. (2016) · Clinical Microbiology Reviews · doi:10.1128/cmr.00102-15 · Cited by 1,430
Chronic hepatitis B virus infection
Seto, W.-K., Lo, Y.-R., Pawlotsky, J.-M., & Yuen, M.-F. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31865-8 · Cited by 555
Marcellin, P., Ahn, S. H., Ma, X., Caruntu, F. A., Tak, W. Y., Elkashab, M., Chuang, W.-L., Lim, S.-G., Tabak, F., Mehta, R., et al. (2016) · Gastroenterology · doi:10.1053/j.gastro.2015.09.043 · Cited by 342
Self-citationPresent and future therapies of hepatitis B: From discovery to cure
Liang, T. J., Block, T. M., McMahon, B. J., Ghany, M. G., Urban, S., Guo, J., Locarnini, S., Zoulim, F., Chang, K., & Lok, A. S. (2015) · Hepatology · doi:10.1002/hep.28025 · Cited by 317
Metadata
- Authors
- Brouwer, W. P., Xie, Q., Sonneveld, M. J., Zhang, N., Zhang, Q., Tabak, F., Streinu‐Cercel, A., Wang, J., Idilman, R., Reesink, H. W., Diculescu, M., Simon, K., Voiculescu, M., Akdogan, M., Mazur, W., Reijnders, J. G. P., Verhey, E., Hansen, B. E., Janssen, H. L. A., & for the ARES Study Group
- Venue
- Hepatology
- Published
- 2015-02-27
- Volume
- 61
- Issue
- 5
- Pages
- 1512-1522
- ISSN
- 0270-9139 (ISSN-L)
- 1527-3350
- OpenAlex
- W2020276240
- Cited by
- 166
- References
- 0
- FWCI
- 14.38
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study). https://app.cochat.ai/papers/10.1002/hep.27586
- The paper
- Brouwer, W. P., Xie, Q., Sonneveld, M. J., Zhang, N., Zhang, Q., Tabak, F., Streinu‐Cercel, A., Wang, J., Idilman, R., Reesink, H. W., Diculescu, M., Simon, K., Voiculescu, M., Akdogan, M., Mazur, W., Reijnders, J. G. P., Verhey, E., Hansen, B. E., Janssen, H. L. A., & for the ARES Study Group. (2015). Adding pegylated interferon to entecavir for hepatitis B e antigen–positive chronic hepatitis B: A multicenter randomized trial (ARES study). Hepatology. https://doi.org/10.1002/hep.27586
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.